“The next pandemic will not kill us because the virus is unstoppable—it will kill us if our response is slower than its spread. Nature will always surprise us. Our only choice is whether we meet that surprise with panic and improvisation, or with vaccines loaded, laboratories ready, factories roaring, and the world prepared to fight back. The clock is already running. There is no rehearsal. This battle needs to be won.”
A.G.
THIS IS A BATTLE THAT NEEDS TO BE WON
Ebola, the 100-Day Race, and the Dangerous Illusion That the Next Pandemic Will Give Us Time
There is no warning shot in a pandemic.
By the time the world understands what is happening, the virus has already begun writing its own timetable.
And the latest Ebola outbreak is a brutal reminder of that reality.
A new Ebola vaccine candidate targeting the Bundibugyo virus is moving from laboratory development toward human testing at remarkable speed. One candidate, an Oxford adenovirus-based vaccine, is already being produced at large scale by the Serum Institute of India. A Moderna mRNA vaccine candidate is expected to enter Phase I clinical testing, focused initially on safety and immune responses.
The extraordinary part is not simply that these vaccines are being developed.
It is how quickly the scientific community is trying to respond to a virus that was not the one everyone had been preparing for.
The original ambition was breathtaking: develop and authorize a new vaccine against an emerging pathogen within 100 days.
This time, the 100-day target will not be met.
But the lesson is far more important than the missed deadline.
We are learning how to move faster.
And in the next pandemic, speed may determine who lives and who dies.
THE VIRUS DOES NOT CARE ABOUT OUR PREPARATIONS
The Bundibugyo strain is a perfect demonstration of the fundamental problem of pandemic preparedness.
Scientists had already developed vaccines against several of the most dangerous filoviruses, including the Zaire Ebola virus, the Sudan virus, and Marburg virus.
Then Bundibugyo came back.
It had not been seen in a major outbreak since 2012.
And suddenly, an entirely different Ebola virus was demanding an entirely different response.
That is the uncomfortable truth about emerging infectious diseases:
We prepare for the threats we know. Nature has the freedom to choose something else.
The current outbreak is expanding rapidly.
According to the figures cited in the interview, there are already 3,748 confirmed infections and 1,657 deaths, with more than 50 deaths reported on a single day.
And those numbers may substantially underestimate the true scale.
Many people are dying at home without being formally registered. Transmission chains remain unidentified.
That means the official statistics are not necessarily a photograph of the epidemic.
They may be a photograph of only the part we can see.
A 40-PERCENT CASE-FATALITY RATE IS NOT A STATISTIC TO IGNORE
Bundibugyo Ebola is not quite as lethal as the notorious Zaire strain.
But "less lethal" does not mean "safe."
The estimated case-fatality rate is around 40 percent.
That is an extraordinary mortality rate for an infectious disease.
And the danger becomes considerably greater when a virus moves beyond isolated communities and into major urban centres.
That has now happened.
Kisangani, a city of approximately 1.6 million people, has been reached by the outbreak.
This changes the equation dramatically.
Kisangani is highly connected to surrounding regions by transportation networks. Unlike isolated communities, an outbreak in a major urban centre has far more opportunities to generate new transmission chains.
The geographical risk therefore becomes enormous.
And the epidemic is already spreading faster than previous Ebola outbreaks.
That combination—rapid transmission, unidentified chains, urban connectivity and substantial mortality—is precisely what pandemic preparedness is supposed to anticipate.
THE CLOCK IS TICKING
The 2018–2020 Ebola epidemic in the same broad region lasted approximately 22 months and produced around 3,480 cases.
The current outbreak has already approached or exceeded that scale in confirmed infections, while continuing to grow.
That comparison should make everyone uncomfortable.
Because the previous outbreak was already exceptionally difficult to control.
There were problems with insecurity.
Contact tracing was difficult.
Communities were sometimes inaccessible.
And public-health workers were operating under extremely challenging conditions.
But there was one enormous advantage:
There was an approved vaccine.
The vaccine Ervebo, designed against the Zaire strain, provided a powerful tool for controlling transmission.
It could be administered rapidly.
It generated protection within roughly 10 days.
And it could be deployed through ring vaccination—vaccinating people around known cases and their contacts to create protective barriers against further transmission.
For Ebola, that is almost the ideal epidemiological weapon.
Because Ebola has a relatively long incubation period, public-health authorities have an opportunity to identify contacts and vaccinate them before they become infectious.
But that weapon was designed for the wrong enemy.
ONE EBOLA VACCINE DOES NOT MEAN ALL EBOLA IS DEFEATED
This is where the science becomes fascinating—and frustrating.
Ervebo uses a vesicular stomatitis virus (VSV) as a vector.
The vector is engineered to display a surface glycoprotein from the Zaire Ebola virus.
The immune system learns to recognize that protein.
If scientists can modify the same VSV platform so that it presents the corresponding surface protein from Bundibugyo virus, they may be able to produce a vaccine capable of generating strong protection against this strain as well.
In theory, that could produce a remarkably powerful outbreak-control tool.
But there is a catch.
Vaccine platforms are not magic.
VSV vaccines can be difficult to develop, manufacture and scale.
Even if the science works, production may take longer than with some adenovirus or mRNA platforms.
That is why researchers are pursuing several technological paths simultaneously.
NEVER BET THE PANDEMIC RESPONSE ON ONE HORSE
The current strategy is essentially a portfolio approach.
Several vaccine candidates are being developed against Bundibugyo.
Some use VSV technology.
Another uses an adenovirus platform, known as ChAdOx1.
Another is based on mRNA technology.
That redundancy is not waste.
It is insurance.
Because nobody knows in advance which platform will prove fastest, safest, most effective or easiest to manufacture at scale.
The lesson from COVID-19 should be permanently burned into global health policy:
Never depend on a single technological platform when the pathogen is moving faster than bureaucracy.
We need multiple vaccines.
Multiple platforms.
Multiple manufacturers.
Multiple production sites.
Multiple regulatory pathways.
And multiple scientific teams working in parallel.
Because if one approach fails, another must already be moving.
THE 100-DAY TARGET IS NOT A PUBLIC-RELATIONS SLOGAN
The ambition to develop a new vaccine within 100 days is sometimes dismissed as unrealistic.
Perhaps it is.
At least today.
But that misses the point.
A target like 100 days is valuable precisely because it forces the entire system to ask:
Why does it take so long?
Why does it take months to move from pathogen identification to vaccine design?
Why are manufacturing facilities not already prepared?
Why do clinical trials take so long to activate?
Why are regulatory procedures so fragmented?
Why aren't prototype vaccines already sitting in laboratories?
Why aren't manufacturers ready to switch production?
Why are we repeatedly forced to build the response infrastructure after the emergency begins?
The objective is not merely to have a vaccine in 100 days.
The objective is to build a system capable of switching into emergency mode almost immediately.
THE PAN-VACCINE: THE HOLY GRAIL OF FILOVIRUS PREPAREDNESS
There is an even bigger idea.
Instead of developing a new vaccine every time Ebola surprises us, why not develop a vaccine capable of protecting against multiple filoviruses?
A pan-filovirus vaccine could potentially protect against several members of the family—including different Ebola strains and Marburg virus.
That would be a game changer.
Filoviruses occur across parts of Africa, with some related viruses also found in Asia.
In certain regions, different filoviruses overlap geographically.
That means healthcare workers entering a high-risk outbreak zone could potentially be vaccinated before the outbreak begins.
Imagine the difference.
Instead of waiting for a mysterious virus to emerge, identifying it, sequencing it, designing a vaccine, manufacturing it, testing it and then trying to distribute it while people are dying—
we could already have protection on the shelf.
That is what preparedness should mean.
BUT THERE IS A PROBLEM WITH PREPARING FOR THE WRONG FUTURE
The world has a tendency to prepare for yesterday's disaster.
Scientists had good reasons to focus on Zaire Ebola, Sudan virus and Marburg virus.
Those pathogens accounted for 47 of the 50 known filovirus outbreaks referenced in the discussion.
From a risk-management perspective, concentrating resources on those viruses made sense.
Until Bundibugyo appeared.
That is the problem.
Preparedness based exclusively on historical frequency can become dangerously rigid.
The pathogen landscape does not respect our spreadsheets.
It does not care about our budgets.
It does not care which virus policymakers consider statistically most likely.
Viruses mutate. Viruses evolve. Viruses move. Viruses surprise us.
And sometimes the pathogen that barely made yesterday's priority list becomes tomorrow's emergency.
THE PRICE OF BEING UNPREPARED
Developing a vaccine capable of helping control this outbreak is estimated to require approximately $525 million.
The immediate requirement is considerably smaller but still enormous:
$135–180 million over the next six months to maintain momentum.
Put that into perspective.
Hundreds of millions of dollars sound like a staggering amount of money.
But compare that with the economic, social and human cost of allowing an epidemic to continue unchecked.
Hospitals become overwhelmed.
Healthcare workers become exposed.
Trade and transportation are disrupted.
Borders become politically contentious.
Communities lose trust.
Schools and workplaces are affected.
Businesses suffer.
Governments scramble.
And thousands—or potentially millions—of people can become caught in the consequences.
Pandemic preparedness is therefore not simply a health expenditure.
It is national security. Economic security. Social stability. And global security.
VACCINES ALONE WILL NOT WIN THIS WAR
There is another uncomfortable reality.
A vaccine cannot compensate for a broken public-health system.
Controlling Ebola requires communities to participate.
It requires effective surveillance.
It requires contact tracing.
It requires rapid diagnosis.
It requires isolation and treatment.
It requires safe burial practices.
It requires healthcare workers who have adequate protection.
And it requires trust.
If people are frightened of authorities, avoid treatment centres or conceal contacts, the virus gains an enormous advantage.
The epidemic therefore becomes a battle not only against a pathogen, but against misinformation, fear, poverty, insecurity, weak infrastructure and distrust.
The virus exploits every weakness in the system.
THE NEXT PANDEMIC WILL NOT NECESSARILY BE EBOLA
And that is perhaps the most important lesson.
The world cannot build a pandemic strategy around one virus.
The threat portfolio is much larger.
High on the preparedness list are families including:
- Coronaviruses
- Arenaviruses
- Orthomyxoviruses
- Filoviruses
- and other pathogen families capable of generating severe outbreaks.
The answer is not to predict precisely which virus will emerge.
That is impossible.
The answer is to develop technologies and systems that can respond regardless of which virus wins the evolutionary lottery.
BUILD THE "VACCINE LIBRARY"
This is where pandemic preparedness becomes something much more sophisticated than stockpiling finished vaccines.
Imagine a global vaccine library.
Not one vaccine.
Hundreds of vaccine concepts.
Multiple technological platforms.
Multiple manufacturers.
Multiple prototype candidates.
Multiple regulatory pathways.
Multiple facilities capable of scaling production.
The moment a dangerous pathogen appears, scientists would not be starting from zero.
They would already have:
the platform.
the manufacturing technology.
the regulatory knowledge.
the clinical infrastructure.
the prototype.
the trained workforce.
the supply chain.
The response would be adaptation—not invention from scratch.
That distinction could save months.
And in a pandemic, months are an eternity.
THE SERUM INSTITUTE MODEL MATTERS
Science alone is not enough.
A vaccine sitting in a laboratory is not a pandemic solution.
It has to be manufactured.
Millions of doses have to be produced.
Then distributed.
Then administered.
That is why large-scale manufacturing capacity is just as important as the scientific breakthrough itself.
A handful of companies possessing the capability to rapidly produce enormous quantities of vaccines can become critical infrastructure for the entire planet.
The pandemic response therefore requires a global manufacturing network that can switch from ordinary production to emergency production when the alarm sounds.
The vaccine factory of tomorrow must be designed for the pandemic that hasn't happened yet.
AND HERE IS THE REALLY BIG LESSON
The Bundibugyo outbreak exposes a fundamental weakness in our thinking.
We tend to imagine pandemics as isolated events:
A virus appears → scientists develop a vaccine → governments distribute it → crisis ends.
Reality is much messier.
Pandemic preparedness is a permanent race between:
viral evolution
and
human innovation.
The virus is continuously changing.
Our response system must therefore be continuously improving.
There is no finish line.
There is no moment when humanity can declare:
"We are prepared."
Preparedness is not a destination.
It is a permanent state of readiness.
WE CANNOT AFFORD TO WAIT FOR THE NEXT SURPRISE
The current outbreak may continue well into next year.
That possibility is not speculation pulled from thin air.
It reflects the geographical spread, the number of cases, difficult operating conditions, unidentified transmission chains and the experience of previous major Ebola epidemics.
And there is a particularly cruel irony here.
By the time a broadly protective filovirus vaccine is ready for advanced testing, this outbreak may already be ending—or it may have become something much larger.
That is why preparedness cannot begin when the outbreak starts.
Preparedness has to begin when there is no outbreak.
That is the only moment when we have time.
THIS IS A BATTLE THAT NEEDS TO BE WON
There is no guarantee that humanity will win the next pandemic battle.
But there is also no reason to enter the fight unarmed.
We now possess extraordinary technologies.
mRNA platforms.
Adenovirus platforms.
Viral-vector technologies.
Rapid genomic sequencing.
Advanced diagnostics.
Artificial intelligence-assisted vaccine design.
Global manufacturing networks.
Modern epidemiology.
And decades of hard-earned experience from Ebola, COVID-19, influenza and other outbreaks.
What we lack is not simply scientific capability.
What we lack is sufficient speed, capacity, coordination and political commitment.
The objective should be brutally simple:
When the next dangerous virus appears, we do not start running.
We are already running.
The laboratories are ready.
The manufacturers are ready.
The regulators are ready.
The clinical trials are ready.
The supply chains are ready.
The healthcare systems are ready.
And the vaccines are already waiting in the pipeline.
Because the next virus will not politely wait for us to catch up.
It will exploit every day we waste.
Every month we delay.
Every factory we fail to build.
Every vaccine platform we fail to develop.
Every outbreak we dismiss because it is happening somewhere else.
The Bundibugyo outbreak is therefore more than an Ebola crisis.
It is a stress test for civilization's pandemic defenses.
And the verdict should be unmistakable:
We don't need to predict the next pandemic. We need to be ready for it.
Because when the alarm finally sounds, there will be no time left to prepare.
This is a battle that needs to be won.
yours truly,
Adaptation-Guide
